Sell RIM!: Against ...
Health Care: Drugs
Catalyst Pharmaceutical Partners Inc. (CPRX: NASDAQ)
$0.57 0.00 | 0.04%
06/04/12 - 03:54 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 0.57 |
| 52 Week High | 2.25 |
| 52 Week Low | 0.50 |
| Avg. Daily Vol. (Mil) | 0.13 |
| Beta (3 year) | 0.81 |
| Share Related Items | |
| Mkt Cap (Mil) | 14.10 |
| Shares Out (Mil) | 24.74 |
| Float (Mil) | 15.75 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 5.40 |
| Current Ratio | 5.60 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.00 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 0.00 |
| Price/Book | 5.19 |
| Price/Cash Flow | -2.40 |
| Per Share Data | |
| Earnings | -0.25 |
| Sales | 0.00 |
| Book Value | 0.11 |
| Cash Flow | -0.24 |
| Business Summary | |
|---|---|
| Catalyst Pharmaceutical Partners, Inc. is a biopharmaceutical Company, focused on the development and commercialization of prescription drugs targeting diseases of the central nervous system with a focus on the treatment of drug addiction and epilepsy. | |
| General Information | |
| 355 Alhambra Circle
Suite 1370 Coral Gables, FL 33134 |
|
| www.catalystpharma.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 6 | |
| CEO: Patrick J. McEnany | |
| Short Interest | |
| Current Month (Mil) | 0.29 |
| Previous Month (Mil) | 0.25 |
| Short Interest Ratio (Days) | 5.00 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -119.50 |
| Return on Investments | -219.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with CPRX
- Portfolio NameUser Type
- ContributorBreakout Stocks Of The Week...
- UserSUPRATRADE EX-1006090013 DE...
- Userzhuangsn
- UserBRR Portfolio 1
- Userjaxplace Portfolio 1
- Usersovnek Portfolio 1
- UserDj Paul
- Userlouiis Portfolio 1
- Usercjthurman Portfolio 1
- Userajsny Portfolio 1
Latest CPRX Headlines from TheStreet
- 5 Stocks Setting Up to Break Out 12.20.11 | 01:12 pm
- Catalyst Announces Commencement Of CPP-109 Investigator-Sponsored Study In Cocaine And Alcohol Co-Dependent Patients 03.29.11 | 08:03 am
- Catalyst Pharmaceutical Partners To Present At The ROTH 23rd Annual OC Growth Stock Conference 03.09.11 | 11:03 am
- Catalyst Pharmaceutical Partners, Inc. Announces Public Offering Of Common Shares 03.08.11 | 09:03 am
- Catalyst Pharmaceutical Partners Promotes Steven R. Miller, Ph.D. To Chief Operating Officer 01.25.11 | 08:01 am
- Catalyst Pharmaceutical Partners To Present At The Biotech Showcase(TM) 2011 Conference 01.04.11 | 08:01 am
- Canadian Intellectual Property Office Grants Broad Patent For The Use Of Vigabatrin/CPP-109 For The Prevention Of Addiction In Pain Management 12.09.10 | 08:12 am
- Catalyst Pharmaceutical Partners Initiates A Registration-Directed U.S. Phase II(b) Clinical Trial In Collaboration With The National Institute On Drug Abuse And Veteran's Administration Cooperative Studies Program 11.18.10 | 08:11 am
- Catalyst Pharmaceutical Partners Announces Third Quarter 2010 Financial And Operational Results 11.16.10 | 08:11 am
- Dr. Richard B. Silverman Joins Catalyst Pharmaceutical Partners' Scientific Advisory Board 11.15.10 | 08:11 am
Press Releases for CPRX
- Vigabatrin/CPP-109 Data To Be Presented At College On Problems Of Drug Dependence Annual Meeting - PR Newswire 06.09.10 | 08:06 am
- Catalyst Pharmaceutical Partners To Present At The MoneyShow Conference - PR Newswire 05.07.10 | 08:05 am
- Catalyst Pharmaceutical Partners Regains Compliance With NASDAQ Minimum Bid Price Rule - PR Newswire 04.26.10 | 11:04 am
- Catalyst Pharmaceutical Partners Signs Definitive Agreement With The National Institute On Drug Abuse To Conduct U.S. Phase II(B) Clinical Trial For Cocaine Addiction - PR Newswire 04.13.10 | 10:04 am
- CPP-109 Clinical Trial Data To Be Presented At The American Society Of Addiction Medicine Annual Medical-Scientific Conference - PR Newswire 04.09.10 | 08:04 am
- Catalyst Pharmaceutical Partners Reports Fourth Quarter And Year-End 2009 Financial Results - PR Newswire 04.01.10 | 08:04 am
- Catalyst Pharmaceutical Partners To Present At The BioNetwork East 2010 Conference - PR Newswire 03.10.10 | 08:03 am
- Catalyst Pharmaceutical Partners To Present Today At 2010 Epilepsy Pipeline Update Conference - PR Newswire 02.25.10 | 08:02 am
- Catalyst Pharmaceutical Partners And The National Institute On Drug Abuse Plan To Initiate U.S. Phase II(b) Clinical Trial For Cocaine Addiction - PR Newswire 02.23.10 | 08:02 am
- Catalyst Pharmaceutical Partners Selected To Present At Epilepsy Conference Highlighting New And Promising Therapies - PR Newswire 02.17.10 | 08:02 am
Partner Headlines for CPRX
- Weekly CFO Buys Highlight: EMC, DVOX, NANX, CPRX, CCRN - GuruFocus 06.04.12 | 01:06 pm
- 7 Stocks Under $6 Poised To Double In 2012 - Seeking Alpha 11.24.11 | 06:11 am
- 6 Biotechs That Could See Huge Gains (Like Inhibitex) - Seeking Alpha 11.11.11 | 09:11 am
- Zacks #1 Rank Additions for Friday - Tale of the Tape - Zacks 10.14.11 | 09:10 am
- Zacks #1 Rank Additions for Monday - Tale of the Tape - Zacks 10.10.11 | 09:10 am
- Morning Market Losers - Benzinga 06.06.11 | 09:06 am
- 7 Big Movers That Investors Must Watch This Week - Seeking Alpha 06.06.11 | 08:06 am
- 7 Dirt-Cheap Takeover Targets in Biotech - Seeking Alpha 06.03.11 | 09:06 am
- Orphan Status for Catalyst Drug - Analyst Blog - Zacks 09.22.10 | 06:09 pm
- Biotech's Slow Week Gets Stirred by a Few Smaller Deals - Seeking Alpha 08.15.10 | 04:08 am
